Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of Fluzone® (Influenza Vaccine) for the 2016-2017 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA) for shipment. This represents the first of more than 65 million total doses of seasonal influenza vaccine manufactured by Sanofi Pasteur that will be delivered to U.S. health care providers and pharmacies beginning in July and continuing throughout the remainder of the year. Sanofi Pasteur plans to increase its supply to respond to the shifting pediatric public health needs.
Seasonal influenza activity typically occurs between October and May and peaks between December and February. However, influenza activity peaked noticeably late last season occurring in early March 2016.1 Influenza seasons are always unpredictable as new influenza strains emerge and strain activity fluctuates throughout the year, making timely vaccination even more important to help protect against the virus, especially for seniors, young children and infants six months of age and older.
To view the multimedia release go to:
http://www.multivu.com/players/English/7842051-sanofi-pasteur-influenza-vaccine/
FileMaker today announced a new version of its development platform that speeds creation of custom solutions that run on iPad, iPhone, Windows, Mac and the web. FileMaker 14 brings point-and-click simplicity to automating business processes, delivering desktop-style application functionality to mobile web browsers and providing productive, engaging experiences on desktops, iOS devices and mobile web browsers.
The announcement coincides with the 30th anniversary of FileMaker software. FileMaker was the brainchild of a bootstrapped startup founded in Massachusetts by four entrepreneurs intent on creating easy-to-use database software.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7318353-filemaker-platform-14/
Nearly four out of five small business owners admit that they have not taken full advantage of national and community resources dedicated to helping small businesses develop and grow, according to a survey recently conducted by Fifth Third Bank.
In advance of Small Business Week May 1-7, Fifth Third Bank (NASDAQ: FITB) conducted a national survey of more than 500 small business owners to assess the landscape – and diagnose common pain points – of U.S. small business owners. According to the results, 81 percent of survey participants said they haven’t worked with local small business resources (e.g., chamber of commerce, SCORE, etc.). Forty-one percent were unsure if the United States Small Business Administration (SBA) had resources to help them. Roughly 38 percent of small business owners say they need help growing revenue and increasing profits.
To view the multimedia release go to:
http://www.multivu.com/players/English/7723852-fifth-third-bank-small-business/
Gen-Probe (NASDAQ: GPRO) announced today the US Food and Drug Administration (FDA) has approved its PROGENSA® PCA3 (Prostate Cancer gene 3) assay, the first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53530-gen-probe-progensa-pca3-prostate-cancer-psa
“Experience Day of Beautiful China” global tour event, hosted by China Intercontinental Communication Center, jointly guided by the State Council Information Office of the People’s Republic of China, China National Tourism Administration and Chinese Consulate General in New York, has begun in the Thomson Reuters building in Times Square, NYC on Sep 14th, 2015.
As the partner of the event, Thomson Reuters gave strong support. Riordan William, Thomson Reuters’ director of global Internet, said: I deem it an honor that you came to Reuters to organize the event. I have been to China, and it is a very attractive country. And I’m so glad to see the combination of advanced technology and culture. We’re looking forward to more cooperation with China.
The Deputy Director of the China Intercontinental Communication Center Jing Shuiqing said in his speech: “Experience Day of Beautiful China” event is our first 3D virtual technology applied to the field of tourism and cultural dissemination. We hope to share the beautiful China by new technology and new means, thus achieving cross-cultural, cross-regional, cross-media communication, and creating a new model of cooperation of tourism and cultural exchanges between China and the US.
To view the multimedia release go to:
http://www.multivu.com/players/English/7629251-beautiful-china-tour-event/
The U.S. Environmental Protection Agency (EPA) has proposed sweeping regulations that would require states to reduce carbon dioxide emissions from the electricity sector by an average of 30 percent nationally. This costly plan is another step in the administration's policies designed to eliminate low cost and reliable electricity and replace it with more expensive and less reliable sources.
"The rule is a stunning attempt to remake the nation's entire electric grid at great cost to households and businesses across the US. Our manufacturing base will become less competitive because of higher electricity prices. The impact of this regulation will be felt by families as they will spend more to heat and cool their homes. Those on fixed incomes and seniors will be forced to pay a disproportionately higher share of their monthly budget on utilities," said Hal Quinn, president and CEO, National Mining Association."
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7221731-national-mining-association-americans-electricity-bill-increase-due-to-epa-regulations/
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received U.S. Food and Drug Administration (FDA) clearance for the ClearSight system.
The ClearSight system is a noninvasive monitor that provides clinicians access to valuable blood volume and blood flow information for patients at moderate or high risk of post-surgical complications, in whom invasive monitoring would not be used.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256451-edwards-fda-clearance-for-noninvasive-hemodynamic-monitoring-system/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Today, HHS’ Administration for Children and Families (ACF), along with the National Responsible Fatherhood Clearinghouse, has launched a new series of public service advertisements (PSAs) recognizing the critical role fathers play in the lives of their children.
The public service campaign created by the non-profit Ad Council coincides with Tell a Joke Day and centers on the popularity and growing trend of telling “Dad” jokes. Through sharing dad jokes, the PSAs aim to communicate to fathers that the smallest moments spent with their children can make the biggest difference in their children’s lives. The ads direct fathers to Fatherhood.gov where users will find helpful tips, tools, information and jokes to help them get more involved with their kids.
To view the multimedia release go to:
https://www.multivu.com/players/English/8156551-ad-council-fatherhood-dad-jokes/
Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61338-raptor-pharmaceutical-procysbi-fda-approval-nephropathic-cystinosis
Cornell University’s School of Hotel Administration and eCornell have launched new on-demand training in service excellence targeting front-line employees. The training consists of eight online lessons, all of which are available 24/7, and is complemented by a Workshop Guide to promote onsite, face-to-face discussion and application of the online lesson concepts. The training explores the foundations of service delivery and empowers employees through practical tools that can be applied to any situation involving internal or external customers.
Service Excellence On-Demand Training provides groups and organizations with a straightforward framework to increase effectiveness for all customer interactions. It provides employees with the skills needed to connect service excellence concepts to the execution of their daily duties, tasks, and responsibilities. Individuals who successfully complete all eight lessons will receive a recognition of their achievement from Cornell University’s School of Hotel Administration.
To view the multimedia release go to:
http://www.multivu.com/players/English/7975651-cornell-university-service-excellence-training/
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7092251-fda-approve-s-exact-sciences-cologuard-screening-test-colorectal-cancer/
